Forsta AP Fonden increased its position in Shire PLC (NASDAQ:SHPG) by 21.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,000 shares of the biopharmaceutical company’s stock after purchasing an additional 21,000 shares during the period. Forsta AP Fonden’s holdings in Shire were worth $20,425,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. Rockefeller Capital Management L.P. purchased a new position in Shire in the 1st quarter worth about $113,097,000. PointState Capital LP raised its position in Shire by 4,642.0% in the 2nd quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock worth $120,067,000 after buying an additional 696,296 shares during the last quarter. Morgan Stanley raised its position in Shire by 25.7% in the 2nd quarter. Morgan Stanley now owns 426,212 shares of the biopharmaceutical company’s stock worth $71,946,000 after buying an additional 87,126 shares during the last quarter. Marshall Wace LLP raised its position in Shire by 33.7% in the 2nd quarter. Marshall Wace LLP now owns 356,002 shares of the biopharmaceutical company’s stock worth $60,093,000 after buying an additional 89,769 shares during the last quarter. Finally, First Trust Advisors LP raised its position in Shire by 1.9% in the 2nd quarter. First Trust Advisors LP now owns 350,477 shares of the biopharmaceutical company’s stock worth $59,161,000 after buying an additional 6,682 shares during the last quarter. Institutional investors own 17.84% of the company’s stock.
A number of equities analysts have weighed in on the company. ValuEngine raised Shire from a “sell” rating to a “hold” rating in a research report on Friday, September 21st. BidaskClub raised Shire from a “sell” rating to a “hold” rating in a research report on Thursday, September 13th. Berenberg Bank lowered Shire from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Evercore ISI lowered Shire from an “outperform” rating to a “market perform” rating and set a $196.00 target price for the company. in a research report on Tuesday, September 4th. Finally, Sanford C. Bernstein lowered shares of Shire from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th. Nine investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Shire presently has a consensus rating of “Buy” and a consensus target price of $200.75.
Shares of NASDAQ SHPG traded down $3.45 during midday trading on Friday, hitting $173.40. 1,388,394 shares of the company’s stock traded hands, compared to its average volume of 1,180,684. Shire PLC has a 1 year low of $123.73 and a 1 year high of $182.36. The firm has a market capitalization of $55.10 billion, a P/E ratio of 11.45, a PEG ratio of 1.61 and a beta of 1.19. The company has a quick ratio of 1.02, a current ratio of 1.55 and a debt-to-equity ratio of 0.45.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.67 by $0.21. The firm had revenue of $3.92 billion during the quarter. Shire had a net margin of 31.06% and a return on equity of 13.22%. Shire’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.73 EPS. As a group, equities research analysts anticipate that Shire PLC will post 15.27 EPS for the current year.
The business also recently disclosed a dividend, which will be paid on Friday, October 19th. Investors of record on Friday, September 7th will be paid a dividend of $0.168 per share. The ex-dividend date of this dividend is Thursday, September 6th. Shire’s dividend payout ratio (DPR) is presently 2.24%.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: Should You Consider an Index Fund?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.